Related Experiment Video

Updated: Jul 12, 2026

Isolation and Functional Characterization of Human Ventricular Cardiomyocytes from Fresh Surgical Samples
14:39

Isolation and Functional Characterization of Human Ventricular Cardiomyocytes from Fresh Surgical Samples

Published on: April 21, 2014

Surgery insight: Septal myectomy for obstructive hypertrophic cardiomyopathy--the Mayo Clinic experience

Joseph A Dearani1, Steve R Ommen, Bernard J Gersh

  • 1Division of Cardiovascular Surgery, Mayo Clinic and Foundation, Rochester, MN 55905, USA. dearani.joseph@mayo.edu

Nature Clinical Practice. Cardiovascular Medicine
|August 23, 2007
PubMed

Insights

Septal myectomy effectively relieves obstructive hypertrophic cardiomyopathy symptoms and outflow tract obstruction in adults and children. This surgery offers excellent long-term survival and symptom improvement, with low operative mortality.

Area of Science:

  • Cardiology
  • Cardiac Surgery

Background:

  • Obstructive hypertrophic cardiomyopathy (oHCM) causes left ventricular outflow tract (LVOT) obstruction and cardiac symptoms.
  • Septal myectomy is the established treatment for oHCM.

Purpose of the Study:

  • To evaluate the efficacy and long-term outcomes of septal myectomy in patients with oHCM.
  • To compare surgical outcomes with non-surgical treatment regimens.

Main Methods:

  • Retrospective analysis of patients undergoing septal myectomy.
  • Assessment of operative mortality, symptom improvement (NYHA class), late survival, and sudden cardiac death risk.

Main Results:

  • Operative mortality for isolated septal myectomy is approximately 1% at experienced centers.
  • 90% of patients experience at least one NYHA class improvement post-surgery.
  • Late survival and reduced sudden cardiac death risk are observed in patients treated with myectomy compared to non-surgical management.

Conclusions:

  • Septal myectomy is a safe and highly effective treatment for oHCM in both pediatric and adult populations.
  • The procedure provides significant, durable symptom relief and improves long-term survival.
  • Myectomy outcomes serve as a benchmark for evaluating emerging non-surgical therapies for oHCM.

More Related Videos

Cox-Maze IV Procedure Concomitant with Valvular Surgery In Situs Inversus Dextrocardia: A Single-Center Experience in China08:42

Cox-Maze IV Procedure Concomitant with Valvular Surgery In Situs Inversus Dextrocardia: A Single-Center Experience in China

Published on: February 11, 2022

Related Concept Videos

Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Cardiomyopathy VII: Pre and Post Operative Nursing Management01:28

Cardiomyopathy VII: Pre and Post Operative Nursing Management

Patients with hypertrophic cardiomyopathy (HCM) and left ventricular outflow tract (LVOT) obstruction who remain symptomatic despite optimal medical therapy may undergo a septal myectomy (Morrow procedure). This procedure involves excising a portion of the hypertrophied septum below the aortic valve using a heart-lung machine to improve blood flow through the LVOT. Effective preoperative and postoperative nursing management ensures successful patient outcomes, minimizes complications, and...
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
Mitral Stenosis III: Medical Management01:26

Mitral Stenosis III: Medical Management

Mitral stenosis, a condition marked by the narrowing of the mitral valve, necessitates an integrated approach for effective management. This approach includes preventative measures, medical therapy, and surgical interventions to reduce symptoms and prevent complications.PreventionPrevention of mitral stenosis primarily focuses on reducing the incidence of bacterial infections, particularly streptococcal infections, which can lead to rheumatic fever and subsequent valvular damage. Timely...